#Germany #Grünenthal #Aachen #SHL Medical #Molly Autoinjector

Grünenthal PRO Collaborates with SHL Medical for Autoinjector Production

Grünenthal PRO, the contract development and manufacturing organization (CDMO) arm of the Grünenthal Group, has announced a significant new partnership with SHL Medical, a global leader in advanced drug delivery systems. This collaboration marks a substantial step forward in the final assembly services for Molly® autoinjectors. The strategic move aims to enhance the efficiency and reliability of drug delivery for pharmaceutical partners, responding to the growing demand in the biopharmaceutical landscape.

Partnership Overview

The agreement will see Grünenthal PRO integrating final assembly, packaging, and labeling operations for the Molly® autoinjector, which is known for its innovative platform technology. The partnership is set to position Grünenthal PRO as a key player in providing high-quality assembly services, thereby streamlining the delivery process for its clients in the pharmaceutical and biotech sectors.

In 2026, Grünenthal plans to augment its capabilities by installing additional pre-validated assembly lines specifically designed for the Molly® 1.0 and 2.25 mL autoinjector platforms at its facility in Origgio, Italy. This investment underscores Grünenthal’s commitment to enhance speed-to-market strategies for its partners. Victor Barbosa, the Executive Vice President of Global Operations at Grünenthal, emphasized that speed-to-market remains a crucial factor in the competitive biopharmaceutical marketplace.

Strategic Advantages

The Molly® autoinjector is designed to be a single-dose device with a modular platform, ideally suited for reducing capital investment and accelerating product timelines for pharma and biotech companies. Its impressive track record in combination product approvals supports its design, making it apt for meeting the evolving demands of future drug delivery mechanisms.

Markus Puusepp, Chief Growth Officer of SHL Medical, emphasized the fruitful collaboration between the two companies that had been taking place over the years. He expressed excitement about welcoming Grünenthal PRO as a strategic partner, which will further build upon the established trust and collaboration.

The collaboration not only enhances Grünenthal’s assembly capacity but also offers SHL customers access to their comprehensive expertise in high-quality contract manufacturing. This synergy reinforces the commitment of both companies to deliver effective solutions that are patient-centric and optimize the drug delivery process.

Implementation of Advanced Technology

As part of this venture, the new assembly line will be procured from SHL Advantec, a subsidiary of SHL Medical. SHL Advantec specializes in providing advanced automation solutions and high-performance precision tooling for various sectors, including healthcare. The integration of such technology will not only optimize production but also ensure adherence to stringent industry standards.

Conclusion

With the biopharmaceutical landscape witnessing rapid advancements, collaborations like that of Grünenthal PRO and SHL Medical are essential to unlocking new potentials in drug delivery solutions. As they gear up for this promising alliance, the emphasis remains on combining cutting-edge technology, industry expertise, and a patient-focused approach to expedite access to essential medications globally.

For more information about Grünenthal PRO, visit www.grunenthal-pro.com and for updates on SHL Medical, check out www.shl-medical.com.